MARKET OUTLOOK Mylan’s salmeterol/fluticasone propionate generic, Wixela...
MARKET OUTLOOK Mylan’s salmeterol/fluticasone propionate generic, Wixela Inhub, is the first substitutable generic for GSK&rsq...
MARKET OUTLOOK Mylan’s salmeterol/fluticasone propionate generic, Wixela...
MARKET OUTLOOK Mylan’s salmeterol/fluticasone propionate generic, Wixela Inhub, is the first substitutable generic for GSK&rsq...
MARKET OUTLOOK Several effective anti-inflammatory agents and...
MARKET OUTLOOK Several effective anti-inflammatory agents and bronchodilators are available for controlling patients’ mild or moderate asthma. However, despite the...
Pediatric asthma pharmacotherapy has two main goals: to address underlying...
Pediatric asthma pharmacotherapy has two main goals: to address underlying airway inflammation and to promote bronchodilation. Physicians use two types of therapy to achieve these goals—mai...
Although a rare disease, idiopathic pulmonary fibrosis (IPF) is one of the...
Although a rare disease, idiopathic pulmonary fibrosis (IPF) is one of the most common interstitial lung diseases (...
Pharmacotherapy for adult asthma has two main goals: address underlying airway...
Pharmacotherapy for adult asthma has two main goals: address underlying airway inflammation and promote bronchodilation. Two types of therapy are used to achieve these goals—maintenance the...
Allergic rhinitis is a chronic immunoglobulin E-mediated respiratory response...
Allergic rhinitis is a chronic immunoglobulin E-mediated respiratory response to environmental allergens. It is typically treated with intranasal corticosteroids, followed by antihistamines, mast......
Coming Soon – May 2019 MARKET OUTLOOK Mylan’s salmeterol/fluticasone...
Coming Soon – May 2019 MARKET OUTLOOK Mylan’s salmeterol/fluticasone propionate generic, Wixela Inhub, is the first substitutable...
The expected date of biosimilar entry is based on multiple factors, including...
The expected date of biosimilar entry is based on multiple factors, including the following: Patent and exclusivity expiry dates. Commercial at......
Dupixent (Sanofi/Regeneron), a first-in-class biologic that inhibits IL-4/IL-...
Dupixent (Sanofi/Regeneron), a first-in-class biologic that inhibits IL-4/IL-13 signaling, was approved for the treatment of eosi......
MARKET OUTLOOK Long-acting beta2 agonist (LABA)/long-acting muscarinic...
MARKET OUTLOOK Long-acting beta2 agonist (LABA)/long-acting muscarinic antagonist (...
DRG Epidemiology's coverage of RSV comprises epidemiological estimates of...
DRG Epidemiology's coverage of RSV comprises epidemiological estimates of key patient populations across the major mature pharmaceutical marke......
Idiopathic pulmonary fibrosis (IPF) is an orphan disease affecting...
Idiopathic pulmonary fibrosis (IPF) is an orphan disease affecting approximately 50,000 people in the United States. It is characterized by an i......
MARKET OUTLOOK The COPD market is continuing its gradual shift away from...
MARKET OUTLOOK The COPD market is continuing its gradual shift away from LAB......
The asthma market consists of many well-established therapies, including...
The asthma market consists of many well-established therapies, including inhaled agents (e.g., GlaxoSmithKline’s Advair/Seretide, AstraZeneca’s Symbicort, Boehringer Ingelheim...
DRG Epidemiology's coverage of AR comprises epidemiological estimates of...
DRG Epidemiology's coverage of AR comprises epidemiological estimates of key patient populations acro...
DRG Epidemiology’s coverage of acute respiratory distress syndrome (ARDS)...
DRG Epidemiology’s coverage of acute respiratory distress syndrome (ARDS) comprises ep...
DRG Epidemiology's coverage of OSA comprises epidemiological estimates of...
DRG Epidemiology's coverage of OSA comprises epidemiological estimates of key patient populations ac......
MARKET OUTLOOK COPD is a progressive inflammatory respiratory tract and lung...
MARKET OUTLOOK COPD is a progressive inflammatory respiratory tract and lung disease characterized by airflow......
Market Outlook The asthma market in the EU5 is highly competitive. A large...
Market Outlook The asthma market in the EU5 is highly competitive. A large number of approved agents are available inc......
